Impact of Definitive Therapy with Beta-Lactam Monotherapy or Combination with an Aminoglycoside or a Quinolone for Pseudomonas aeruginosa Bacteremia

• Ioannis A. Bliziotis,

  Affiliation Alfa Institute of Biomedical Sciences (AIBS), Athens, Greece

  ⨯
• Nicola Petrosillo,

  Affiliation National Institute for Infectious Diseases “L. Spallanzani”, Rome, Italy

  ⨯
• Argyris Michalopoulos,

  Affiliations Alfa Institute of Biomedical Sciences (AIBS), Athens, Greece, Intensive Care Unit, “Henry Dunant” Hospital, Athens, Greece

  ⨯
• George Samonis,

  Affiliation Department of Internal Medicine, University Hospital of Heraklion, Heraklion, Greece

  ⨯
• Matthew E. Falagas

  * E-mail: m.falagas@aibs.gr

  Affiliations Alfa Institute of Biomedical Sciences (AIBS), Athens, Greece, Department of Medicine, “Henry Dunant” Hospital, Athens, Greece, Department of Medicine, Tufts University School of Medicine, Boston, Massachusetts, United States of America

  ⨯